Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus NEOSTIGMINE METHYLSULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus NEOSTIGMINE METHYLSULFATE.
ARICEPT vs NEOSTIGMINE METHYLSULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Inhibits acetylcholinesterase at the neuromuscular junction, increasing acetylcholine availability and enhancing cholinergic transmission.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
0.5-2.5 mg intravenously or intramuscularly every 2-4 hours as needed for reversal of neuromuscular blockade or treatment of myasthenia gravis; for reversal of non-depolarizing neuromuscular blockade, 0.03-0.07 mg/kg intravenously with anticholinergic.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal elimination half-life is approximately 0.7 to 1.2 hours (mean 0.8 h) in healthy adults. In renal impairment, half-life may be prolonged up to 3-4 hours, requiring dose adjustment.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Renal excretion of unchanged drug accounts for approximately 50% of elimination; the remainder is metabolized by microsomal enzymes and excreted in urine as metabolites. Biliary/fecal elimination is minimal (<5%).
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor